TWD 13.85
(-0.72%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 350.07 Million TWD | 5.26% |
2022 | 332.57 Million TWD | -4.48% |
2021 | 348.18 Million TWD | -16.22% |
2020 | 415.56 Million TWD | -8.9% |
2019 | 456.14 Million TWD | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 336.51 Million TWD | -3.87% |
2024 Q2 | 336.51 Million TWD | 0.0% |
2023 FY | 350.07 Million TWD | 5.26% |
2023 Q2 | 337.91 Million TWD | 0.0% |
2023 Q1 | 337.91 Million TWD | 1.61% |
2023 Q3 | 350.07 Million TWD | 3.6% |
2023 Q4 | 350.07 Million TWD | 0.0% |
2022 Q3 | 332.57 Million TWD | 0.0% |
2022 Q4 | 332.57 Million TWD | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Allied Biotech Corporation | 2.07 Billion TWD | 83.161% |
GeneFerm Biotechnology Co., Ltd. | 1.17 Billion TWD | 70.216% |
Easywell Biomedicals, Inc. | 1.21 Billion TWD | 71.158% |
TTY Biopharm Company Limited | 9.87 Billion TWD | 96.455% |
Synmosa Biopharma Corporation | 11.72 Billion TWD | 97.015% |
Orient EuroPharma Co., Ltd. | 10.81 Billion TWD | 96.762% |
Center Laboratories, Inc. | 27 Billion TWD | 98.704% |
Tien Liang BioTech Co., Ltd. | 654.03 Million TWD | 46.475% |
Orient Pharma Co., Ltd. | 2.56 Billion TWD | 86.34% |
InnoPharmax Inc. | 524.19 Million TWD | 33.217% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 1.99 Billion TWD | 82.434% |
Excelsior Biopharma Inc. | 1.57 Billion TWD | 77.806% |
DV Biomed Co., Ltd. | 1.81 Billion TWD | 80.687% |
Foresee Pharmaceuticals Co., Ltd. | 1.86 Billion TWD | 81.193% |
Handa Pharmaceuticals, Inc. | 3.03 Billion TWD | 88.474% |
Anxo Pharmaceutical Co., Ltd. | 2.21 Billion TWD | 84.221% |
Alar Pharmaceuticals Inc. | 973.2 Million TWD | 64.029% |
Winston Medical Supply Co., Ltd. | 801.77 Million TWD | 56.338% |
Mercury Biopharmaceutical Corporation | 438.07 Million TWD | 20.088% |
Bioray Biotech Co., Ltd | 542.64 Million TWD | 35.488% |
TSH Biopharm Corporation Limited | 1.39 Billion TWD | 74.992% |